Antibodies to hepatitis A virus (anti-HAV) were measured in children from two separate vaccine trials (n Å 70) 4 weeks after a dose of inactivated hepatitis A vaccine (VAQTA). The geometric mean titers (GMTs) of anti-HAV were 49.3 and 45.2 mIU/mL by immunoassay, while reciprocal GMTs of neutralizing anti-HAV were 6.5 and 15.0 by an 80% radioimmunofocus inhibition test (RIFIT) and 55.6 and 92.0 by antigen reduction assay (HAVARNA). The GMT of antibody detected by radioimmunoprecipitation (RIPA) was §401. These data establish serologic correlates of protection against disease and show that RIPA is most sensitive for detection of early vaccine-induced antibody. Sera collected from adults (n Å 20) 7 days after administration of immune globulin contained similar antibody levels by immunoassay (45.1 mIU/mL) and slightly higher GMTs of neutralizing antibody (27.5 by RIFIT and 146 by HAVARNA) but negligible precipitating antibody (GMT, 5.6). These results are best explained by differences in the affinity of antibodies for virus following active versus passive immunization.
Inactivated hepatitis A virus (HAV) vaccines are safe and
In a controlled clinical trial, a formalin-inactivated hepatitis A vaccine (VAQTA; Merck Research Laboratories, West highly effective in prevention of symptomatic hepatitis A in immunized children, and they offer substantial promise for Point, PA) [8, 9] induced complete protection against clinically apparent hepatitis A (100% observed efficacy; confidence intercontrol of this disease [1 -3] . Although the immunologic correlates of protection are not well-defined, the well-documented val [CI] , 97% -100%) by 30 days following administration of a single 25 -antigen unit (U) dose to children aged 2 -16 years ability of passively transferred antibodies to protect against hepatitis A suggests that the protection afforded by active im- [2] . Here we characterize the protective antibody response present 4 weeks after such immunization. Antibodies to HAV were munization with formalin-killed virus vaccines is due principally if not entirely to the production of circulating antibodies measured by conventional solid-phase immunoassay (modified HAVAB) in comparison to an international reference reagent, capable of neutralizing HAV [4, 5] . Passive immunization with immune globulin (IG) at usual doses (0.02 -0.06 mL/kg of by two different assays for HAV-neutralizing antibodies, the radioimmunofocus inhibition test (RIFIT) [10] and HAV antibody weight) results in only low levels of such antibodies and generally does not lead to detectable seroconversion when gen reduction assay (HAVARNA) [11] , and by a novel radioimmunoprecipitation assay (RIPA) for detection of anti-HAV paired serum samples are tested by commercially available competitive inhibition immunoassays for anti-HAV antibodies [12] . We describe protective levels of vaccine-induced anti-HAV antibodies as defined by each of these assay methods (e.g., HAVAB; Abbott, Abbott Park, IL) [6, 7] . While these low levels of serum anti-HAV antibodies provide a relatively and compare these results with those obtained in a cohort of adults who had received passive immunization with IG. high degree of clinical protection against disease, the minimal protective level of anti-HAV is not known.
Materials and Methods
Study subjects. Serum specimens were collected from children a single 25-U dose of vaccine was randomly selected from one of JID 1997; 176 (July) demonstration of efficacy, a subset of enrolled children received a 3 H-labeled HAV RIPA for anti-HAV. This assay measures the ability of antibodies present in a serum sample to immunoprecipi-25-U booster dose of vaccine Ç24 weeks after their primary dose.
tate metabolically labeled HAV particles and was carried out as A subset of 20 immunized children (mean age, 7.8 years) who had described previously [12] . On the basis of results with antibodynot experienced clinical signs or symptoms of hepatitis A was negative sera, serum dilutions were considered positive for precipiselected randomly, and sera collected prior to and 4 weeks after tating antibodies if they resulted in at least 30% precipitation of both primary (weeks 0 and 4) and booster (weeks 24 and 28) the labeled virus: cpm pellet § 0.3(cpm pellet / cpm supernatant ). immunizations were tested for anti-HAV activity. These results Statistical methods. Statistical comparisons were performed were compared with antibody levels in 20 healthy adult subjects among vaccine study populations by using analysis of variance on (mean age, 27.3 years) 7 days after administration of a single the log of the titer. Pairwise comparisons were declared significant intramuscular injection of IG (0.06 mL/kg) (MRL-005).
when the probability from a least significant difference test was Modified HAVAB RIA for anti-HAV. Antibody to HAV was õ.05. Summary measures are reported as GMTs along with their measured by a modification of the commercial HAVAB RIA (Abassociated 95% CIs. Booster responses were studied by a paired bott). This modified HAVAB was carried out by mixing 100 mL comparison between log titers of 28-and 24-week samples. of serum with 100 mL of 125 I-labeled anti-HAV, instead of mixing Booster increase is reported as a fold rise (95% CI); an interval 10 mL of serum and 200 mL of 125 I-labeled anti-HAV as directed that excludes 1 signifies a statistically significant booster response. by the manufacturer [13, 14] . Quantitation of antibody activity
The association between immunologic correlates was studied by was based on a standard curve constructed from a serial 2-fold concordance analysis, which seeks to establish the linear agreement dilution of the World Health Organization's reference immunobetween measurements (''linear agreement'' in the analytic sense globulin (5-320 mIU/mL) [15] . All samples and standards were refers to the agreement to a line with slope equal to 1) [17] . diluted in normal human serum as required. Extensive testing has
The concordance correlation coefficient (95% CI) as well as the demonstrated that levels of antibody as low as 5 mIU/mL can be concordance slope (95% CI) are reported. reliably detected by this method [14] . However, the counts per minute (cpm) value obtained from the 10 mIU/mL point on the standard curve was selected as a more conservative break point for positivity in the modified HAVAB.
Results

RIFIT for neutralizing antibody to HAV. This assay for serum
Neutralizing antibody response to inactivated HAV vaccine.
neutralizing antibody is based on the ability of anti-HAV to inhibit Sera collected from 70 children at week 4 after a single dose the development of macroscopic foci of viral replication in cells overlaid with agarose [10, 16] . RIFIT was carried out as described By RIFIT, 12 (60%) of 20 study subjects were positive for neutralizing anti-HAV at week 24 (reciprocal GMT, 10.9), could not be applied to isolated preimmunization specimens.
To assess the neutralizing antibody response to inactivated while all 20 subjects were positive at week 28 after the booster dose (reciprocal GMT, §543). The lesser, 50-fold increase HAV vaccine following a second, booster dose of vaccine, sera collected from the 20 MRL-023 study participants at weeks 24 observed in RIFIT titers between weeks 24 and 28 (table 2) reflects the absence of end-point titrations with 16 (80%) of and 28 (before and 4 weeks after a 25-U booster immunization) were assayed for anti-HAV (table 2). The GMTs of anti-HAV 20 week 28 sera, which were positive at the highest dilution tested (1:800). However, booster responses were statistically determined by modified HAVAB were 52.9 and 9670 mIU/ mL at weeks 24 and 28, respectively. These results demonstrate significant when measured by any of the three assay methods (table 2) . the persistence of antibody up to 24 weeks after primary immu- Table 2 . Measurement of antibody to HAV in MRL-023 study subjects at 4, 24, and 28 weeks. A comparison of RIFIT and HAVARNA titers in individual anti-HAV activity by RIPA at 1:8 and 1:80 serum dilutions.
A representative sample of these results, showing the percentserum samples revealed only a weak correlation when only 4-and 24-week sera were examined in a combined analysis of age of radiolabel precipitated by paired serum samples at both dilutions, is depicted in figure 3 . With most preimmunization the MRL-020 and MRL-023 studies (figure 1). This low level of correlation may have been due to a combination of factors, serum samples, less virus was precipitated at the 1:80 dilution than at the 1:8 dilution, reflecting less nonspecific precipitation including interassay variability, the discrete nature of the neutralization assay measurements, and the narrow range of reof the virus at the higher serum dilution. In contrast, dilution had an opposite effect with most sera collected after immunizasponse within each sampling interval. The interassay variability appeared to be less with RIFIT than with HAVARNA. In replition. Generally higher precipitation values were obtained at 1:80 compared with 1:8 serum dilutions, indicating a prozone cate assays, only 1 of 47 paired results obtained by RIFIT differed by a ú4-fold factor, while this was the case with 8 effect with many of these postimmunization sera (figure 3). To establish criteria for positivity in this RIPA, an extended panel of 36 replicate HAVARNA results (data not shown). A stronger correlation between RIFIT and HAVARNA was evident when of paired sera from the MRL-020 study was tested at both 1:8 and 1:80 dilutions. When preimmunization sera (n Å 40) were sera collected from MRL-020 study participants at week 28 (following booster immunization) were included in the analysis tested at a 1:8 dilution, the mean ({SD) percentage of label precipitated was 7.98% { 4.66%. At a 1:80 dilution, the mean (figure 1). Similarly, titers obtained in either virus neutralization assay correlated with the antibody content of serum as percentage of label precipitated with the preimmunization sera (n Å 38) was 5.98% { 4.08%. Comparable results with paired determined by quantitative modified HAVAB (figure 2). Both neutralization assays were able to detect antibody concentraserum samples collected 4 weeks after immunization were 43.0% { 19.3% (1:8 dilution) and 66.0% { 16.4% SD (1:80 tions below 100 mIU/mL (the approximate detection limit for the standard HAVAB test), although many such sera were dilution). On the basis of these results, serum samples capable of precipitating §30% of label at either 1:8 or 1:80 serum negative by RIFIT. As shown in figure 2 (top), all of the postimmunization serum samples that were negative by RIFIT dilutions were considered positive for HAV-specific precipitating antibodies. By application of this conservative criterion, (titer õ1:8) contained õ100 mIU of antibody/mL by modified HAVAB.
each of the preimmunization sera was negative by RIPA, while 37 of 38 postimmunization sera were positive, 26 (68%) at a Detection of vaccine-induced antibodies by immunoprecipitation of slight increase in antibody content between weeks 4 and 24 effort to conserve the labeled antigen. At this dilution, none of the MRL-023 sera precipitated §30% of the virus ( figure 4A ). suggested by modified HAVAB (GMT, 45.2 vs. 52.9) and slightly lower GMTs determined by both RIFIT and HAVCorrelation of RIPA titers with serum neutralizing antibody titers and antibody content of sera determined by modified ARNA at 24 weeks (table 1). There was substantial variation in the percentage of virus precipitated by paired sera collected HAVAB. The titer of precipitating antibody determined by the semiquantitative RIPA (1:8, 1:80, and 1:800 dilutions) corfrom individual subjects at 4 and 24 weeks: 10 subjects showed a substantial increase from week 4 to 24, while 7 subjects had related well with other measures of anti-HAV response following immunization with inactivated HAV vaccine. Thirteen of little change and 3 demonstrated decreases in the proportion of virus precipitated at the 1:8 dilution (data not shown). At a 40 sera collected at weeks 4 or 24 after a single dose of vaccine in the MRL-023 study had relatively low but detectable RIPA 1:80 dilution of serum, all 20 subjects were positive by RIPA at week 4, while 19 (95%) of 20 were positive at week 24 activity (titer £ 1:80). Only 5 (38%) of these 13 sera tested positive by RIFIT, while 24 (92%) of 26 sera with high RIPA (figure 4B, C). At a 1:800 dilution, 14 (70%) of 20 week 4 sera and 12 (60%) of 20 week 24 sera were positive. Following activity (titer §1:800) had RIFIT titers §1:8. Similarly, compared with sera that had low RIPA activity, sera with high the booster immunization at week 24, sera from all 20 children were strongly positive by RIPA at all three dilutions tested RIPA activity had greater neutralizing antibody activity determined by HAVARNA (reciprocal GMT, 138 vs. 33.7) and (GMT, §1:800) ( figure 4D ). Preimmunization sera from most MRL-023 subjects were tested only at a 1:8 dilution in an greater antibody content determined by modified HAVAB (65.3 vs. 29.8 mIU/mL). High serum neutralizing antibody recipients participating in the MRL-020 and MRL-023 studies (table 1) . Thus, although immunoassay results indicated similar and HAVAB antibody titers at week 28, following booster immunization at 24 weeks, correlated with RIPA titers §1:800 antibody levels in passively and actively immunized groups, significant differences were evident in the neutralization assays: in each of the 20 subjects tested (table 1) . In addition, booster immunization resulted in an increase in the fraction of labeled P õ .01 for RIFIT titers in either MRL-020 or MRL-023 (vaccine) versus MRL-005 (IG), while P õ .01 and P Å .17 virus precipitated at each of the serum dilutions tested (cf. figure 4C and 4D) .
for HAVARNA titers in MRL-020 and MRL-023 (vaccine) versus MRL-005 (IG), respectively. These results suggest that
Comparison of neutralizing antibody titers present following immunization with inactivated HAV vaccine and administration
there may be qualitative differences in the antibodies present shortly after passive and active immunization, with lower levels of IG. IG administered intramuscularly in a dose of 0.06 mL/ kg results in highly effective but relatively short-term protecof virus-neutralizing activity associated with similar antibody levels measured by modified HAVAB following immunization tion against clinical hepatitis A [5] . This protection is due exclusively to the presence of circulating, passively transferred with inactivated HAV vaccine (cf. figures 5 and 2). Antibody detected by RIPA following administration of IG. antibodies to HAV. Thus, it was of interest to compare the levels of antibodies detectable after immunization with inactiSera collected from adult subjects in the MRL-005 study 7 days after administration of IG were tested for the presence of vated vaccine with those present after administration of IG. As shown in table 1, the level of antibody detectable by modified precipitating antibodies at 1:8 and 1:80 dilutions. Surprisingly, only 8 (40%) of 20 sera were positive, and none of these sera HAVAB shortly (7 days) after administration of IG to a group of 20 adults (MRL-005 study) was similar to that present in had RIPA titers ú1:8 ( figure 6 ). The GMT of antibody detected by RIPA in sera collected after administration of IG was only both groups of children studied 4 weeks after they were immunized with a single dose of inactivated vaccine: 45.1 mIU/mL 5.6, much lower than the GMT of §401 found in sera collected 4 weeks after administration of inactivated HAV vaccine in vs. 49.3 (MRL-020, P Å .45) and 45.2 mIU/mL (MRL-023, P Å .98). However, all 20 of the IG recipients were positive the MRL-023 study (P õ .01), even though these sera contained comparable titers of antibody measured by modified HAVAB for neutralizing antibodies by RIFIT, compared with only 34 (49%) of 70 vaccine recipients (table 1) . Similarly, all 16 tested (P Å .98) (table 1). These results confirm that there are significant qualitative differences in circulating anti-HAV antibodies recipients of IG had neutralizing antibody detectable by HAV-ARNA. The reciprocal GMTs of neutralizing antibody meapresent following passive and active immunization that are not reflected in titers obtained with the modified HAVAB assay sured by either assay were higher in IG recipients (27.5 and 146 for RIFIT and HAVARNA, respectively) than in vaccine ( sive and active forms of immunization were particularly evident munoglobulins present in both lots efficiently precipitated labeled virus at concentrations between 3 and 300 mg/mL (data when the antibody titers of individual sera as determined by RIPA were compared with antibody content measured by modinot shown). However, these results are consistent with the low RIPA activity found in IG recipients. Assuming an even and fied HAVAB (figure 7).
The very low precipitating antibody activity found in IG complete distribution of passively transferred immunoglobulin within the extracellular fluid compartment (Ç25% of body recipients prompted us to consider whether the cold ethanol fractionation method used for the isolation of immunoglobulin mass), expected peak serum concentrations of passively transferred IgG would be Ç40 mg/mL. Thus, at a 1:8 serum dilution, from plasma pools during the manufacture of IG might be responsible for loss of activity in the RIPA. We therefore asthe maximum concentration of passively transferred IgG would be Ç5 mg/mL, which is at the lower end of the range of sayed two separate lots of IG (GAMMAR; Armour Pharmaceutical, Collegeville, PA) for precipitating antibody activity the quantity of transferred immunoglobulin would be below their age (mean, 7.8 vs. 7.9 years) and level of antibody measured by modified HAVAB assay 4 weeks after primary immuthe limits of detection.
nization (42 vs. 45.2 mIU/mL) (tables 1, 2) [2] . In addition, we also tested sera collected from a second cohort of children Discussion (MRL-020, n Å 50) who had been immunized 4 weeks previously with the same dose of a different lot of this vaccine. The placebo-controlled trial of VAQTA carried out in Mon-
The GMT of antibody measured by solid-phase RIA (modiroe, New York, by Werzberger et al. [2] (MRL-023) demonfied HAVAB) ranged from 45.2 to 52.9 mIU/mL in the various strated a very high level of efficacy in prevention of clinical groups of sera tested (tables 1, 2), which is much lower than hepatitis A [2] . No cases of hepatitis A were observed among GMTs reported for seropositive persons who acquired antibodthe immunized children in this study later than 16 days after ies to the virus following natural infection: 3485 mIU/mL [7] intramuscular administration of a single 25-U vaccine dose, and 10,700 mIU/mL [19] . Similarly, titers of antibody meaand statistically significant protection was evident by 30 days.
sured by the neutralization assays were much lower than those To characterize the serologic correlates of protection induced present following natural infection [10, 11] . These low levels by a single dose of this HAV vaccine, several different assays are near the limits of detection in the neutralization assays, were used to measure antibodies to HAV in serum samples leading to considerable interassay variability in titers obtained collected Ç4 and 24 weeks after immunization from a ranwith individual sera. While this interassay variability detracts domly selected subset (n Å 20) of the children who participated from the use of both the RIFIT and HAVARNA for measuring in this study. These 20 children were representative of the larger cohort of MRL-023 study participants as reflected by the early antibody response to inactivated HAV vaccine, these larly paired RIFITs, samples collected 4 weeks after immunization caused a §50% reduction in radioimmunofoci relative to preimmunization samples in only 41 (77%) of 53 children at a 1:8 serum dilution (data not shown). Since the HAVARNA was positive in 98% of children at this serum dilution (table  1) , it is in fact more sensitive than the 50% RIFIT. This may be due to neutralization of second-cycle infections by residual antibody in the HAVARNA cultures, a phenomenon that would not affect the quantal RIFIT. Differences in RIFIT and HAV-ARNA titers are unlikely to reflect antigenic differences between the strains of HAV used in the two tests [20] . Previous reports have examined anti-HAV antibody levels present in serum following administration of IG and have sug- efficacy [6, 7] . Indeed, the levels of antibody detected by modified HAVAB in serum from children who were protected by immunization with the inactivated HAV vaccine were similar to those present following administration of IG (45.1 mIU/mL, assays provide unique information concerning the biologic activity of the anti-HAV antibody induced by immunization. Untable 1). However, the neutralizing antibody levels as measured by RIFIT or HAVARNA were significantly lower in the immufortunately, both of these assays are technically demanding and exceptionally labor-intensive.
nized children than in the adult recipients of IG. Only 39 (56%) of 70 children were positive for neutralizing antibodies by The neutralization results summarized in tables 1 and 2 suggest that the RIFIT is considerably less sensitive than the HAV-RIFIT, while all 20 IG recipients tested positive by this assay (table 1) . However, it is not surprising that the actively immu-ARNA. There are several reasons for this. First, RIFIT titers are based on the dilution of serum before mixing it with virus, nized children were protected despite their significantly lower neutralizing antibody responses. Neutralizing antibody activity while HAVARNA titers reflect the final dilution in the virusserum mixture. These previously established conventions lead to a 2-fold inflation of HAVARNA titers. However, greater importance can be attributed to differences in the criteria for positivity in the assays: §80% reduction in radioimmunofoci in the RIFIT compared with §50% reduction in viral antigen expression in the HAVARNA. Fifty percent reduction end points can also be calculated for the RIFIT [10], resulting in considerably higher titers but reducing specificity at low serum dilutions. For example, the calculated GMT of neutralizing antibodies based on a 50% reduction of radioimmunofoci (50% RIFIT) with the 50 specimens collected from MRL-020 participants 4 weeks after immunization was 63.4 (data not shown), compared with 6.5 by the 80% RIFIT and 55.6 by HAVARNA (table 1). Only 2 of the 70 children studied in this report had 50% RIFIT titers £1:8 by 4 weeks after immunization. However, many HAVAB-negative preimmunization sera cause §50% nonspecific reduction of radioimmunofoci at a serum dilution of 1:8 (data not shown). In contrast, use of the 80% end point results in a very high level of specificity, as only 1 of 70 preimmunization sera generated a positive result by this criterion at a 1:8 dilution.
Nonspecific reductions in antigen expression are also ob- RIFIT, required the testing of paired serum samples. In simi- The RIPA was by far the most sensitive method for detection The qualitative differences between antibodies present in late convalescence (IG) and shortly after active immunization of anti-HAV following immunization of children with inactivated HAV vaccine (table 1) . However, while serum from 62 may reflect significant differences in antigen presentation, the total immunogenic mass of antigen, or simply the amount of of 63 children obtained 4 weeks after a single dose of vaccine were positive in the RIPA, this was true for only 8 of 20 time elapsed since exposure to antigen. They are unlikely to represent significant qualitative differences in the viral antigen adult IG recipients (table 1) . Moreover, while the GMT of precipitating antibodies in MRL-023 study subjects was itself. Although formalin inactivation has been shown to destroy some immunogenic epitopes on the surface of the closely §1:401 by 4 weeks after a single dose of the vaccine, none of the adult IG recipients tested positive by RIPA at a ú1:8 related poliovirus [24] , we have not identified consistent differences in the reactivities of multiple neutralizing monoclonal serum dilution. Despite this, the GMTs determined by modified HAVAB titers were comparable following active or passive antibodies when these were tested in solid-phase immunoassays against native and formalin-inactivated HAV virions and empty immunization, while the GMTs of neutralizing antibody in the IG recipients either equaled or exceeded those present in the capsids (Lemon SM, Lewis JA, unpublished data). It is likely that increases in antibody activity following booster immunizaimmunized children (table 1). The contrasting RIPA activities, despite similar HAVAB and neutralizing antibody activities, tion (table 2, figure 5 ) are associated with maturation of the antibody response and increased antibody affinity, although suggest important differences in the affinity of the anti-HAV antibodies present after active and passive forms of immunizathis was not assessed in this study. Such booster responses should enhance and extend the duration of the protective antition. Compared with the neutralization assays, which use very small virus inocula and are likely to be biased strongly toward body response and are likely to be required for long-term protection following administration of inactivated HAV vaccine. detection of high-affinity antibody, the RIPA uses a very large amount of virus and is likely to be less sensitive to differences in antibody affinity under the conditions of the test. The sensi-
